Clinical Research Directory
Browse clinical research sites, groups, and studies.
Caplyta in Borderline Personality Disorder
Sponsor: University of Chicago
Summary
The primary objective of the proposed study is to evaluate the safety and efficacy of Caplyta (lumateperone) in adults with borderline personality disorder (BPD). Sixty subjects with BPD will be randomized in a 1:1 fashion to either Caplyta (42mg/day) or matching placebo for 8 weeks of active treatment. The hypothesis to be tested is that Caplyta will result in greater rates of reduction in symptoms of BPD compared to placebo (improvement in symptoms will be indicated by lower scores on established outcome measures of BPD symptoms that have been used in prior studies).
Official title: A Double-Blind, Placebo-Controlled Study of Caplyta in the Treatment of Borderline Personality Disorder
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-05-10
Completion Date
2025-12-31
Last Updated
2026-07-29
Healthy Volunteers
No
Conditions
Interventions
Caplyta
Atypical antipsychotic
Placebo
Pill that contains no medicine.
Locations (1)
University of Chicago Medical Center
Chicago, Illinois, United States